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Abstract
We conducted this study to examine the effects of safflower seed granular tea containing physiologically active polyphenols on antioxidative
activities and bone metabolism. Forty postmenopausal women ages 49 to 64-years were recruited from Daegu and Gyeongbuk and were randomly
assigned to either a safflower tea supplement (Saf-tea) group (n = 27) or a placebo group (n = 13). The Saf-tea group received 20 g of safflower
seed granule tea per day containing a 13% ethanol extract of defatted safflower seeds, whereas the placebo group received a similar type of tea
that lacked the ethanol extract. No significant changes in nutrient intake for either the placebo or Saf-tea groups were observed before or after
the study period, except vitamin A intake increased after 6 months in the Saf-tea group. Dietary phytoestrogen intakes were similar in the Saf-tea
group (60.3 mg) and placebo group (52.5 mg). Significant increases in plasma genistein and enterolactone were observed in the Saf-tea group.
After 6 months of supplementation, serum levels of antioxidant vitamins such as α-tocopherol and ascorbic acid increased significantly, and TBARS
levels decreased in the Saf-tea group compared to the placebo group. Serum osteocalcin levels were reduced (P< 0.05) in the Saf-tea group after
6 months, whereas serum osteocalcin did not change in the placebo group. Urinary deoxypyridinoline/creatinine excretion was not different between
the two groups at baseline, and did not change in either group after 6 months. Bone mineral density decreased significantly in the placebo group
(P< 0.01) but not in the supplemented group. It was concluded that polyphenols (72 mg/day), including serotonin derivatives, in the Saf-tea had 
both antioxidant and potential bone protecting effects in postmenopausal women without liver toxicity.
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Introduction3)
Safflower (Cathamus tinctorius L.) seeds are a good source 
of edible oil rich in α-linoleic acid (n-6), which has a 
hypocholesterolemic effect. Safflower seeds have long been used 
clinically in Korea to promote bone formation and to prevent 
osteoporosis [1]. Several reports suggest that safflower seed 
powder or extract promotes recovery from bone fractures and 
stimulates differentiation of osteoblasts in rats [2-5]. Our previous 
studies showed that mixed polyphenol compounds extracted from 
defatted safflower seeds stimulates proliferation of ROS 17/2.8 
osteoblast-like cells [6,7]. Furthermore, feeding the seed powder 
[6] and its defatted ethanol extract [7] markedly attenuates bone 
loss in ovariectomized rats. Kang et al. [8] and Kim et al. [9] 
isolated and identified phenolic compounds from roasted safflower 
seeds, and found that safflower seeds were a rich source of not 
only phytoestrogen-like flavones (acacetin and acacetin 7-O-glucoside) 
and lignans (matairesinol and 8-hydroxyarctigenin), but also 
serotonin derivatives (N-feruloylserotonin and N-(p-coumaroyl) 
serotonin) that exhibit antioxidant activity in vitro [8,9]. More 
recently, we showed that a water extract of germinated safflower 
seeds has proliferative and differentiation effects on mouse 
calvarial bone cells, and a major component for the effects was 
trachelogenin [10].
Therefore, seed components with bone-forming effects can be 
utilized as health foods to prevent osteoporosis in postme-
nopausal women. Safflower seed tablets have been formulated 
as a health food by simply grinding and pressing seed powder, 
but consumers complained due to the rancidity of the tablet 
contents during storage. To make up for the shortcomings of 
such tablets, tea-bag [11] and drink-type products [11-13] have 
been prepared using safflower seed powder and ethanol extracts. 
These products have been tested for antioxidant activity [12], 
sensory qualities, and product quality characteristics [11-13] but 
not for their physiological effects in animals and humans. We 
prepared a granule-type tea, including an ethanol extract of 
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Ingredient Safflower tea (g) Placebo tea (g)
Ethanol extract of defatted safflower seeds 13 0
Extract of ssangwha
1) 10 10
Soy isoflavone
2) 0.3 0
Glucose 10.7 10.7
Mannitol 54 54
Maltodextrin 5 18.3
Lactose 5 5
Sodium silicoalumenate 2 2
Total amount 100 100
1) Rubus  coreanus-Atractylodes  japonica
2) 30%  soy  isoflavone
Table 1. Compositions of the safflower and placebo teas defatted safflower seeds, and reported the hypolipidemic and 
antioxidant effects of the tea in ovariectomized rats [14]. In the 
present study, we supplemented with the same safflower granular 
tea to determine the effects on bone metabolism and antioxidant 
status markers in postmenopausal women. 
Subjects and Methods
Subjects
Subjects living in the Daegu-Gyeongbuk area were selected, 
including 50 post-menopausal women with ages between 49 and 
64-years who had not been treated with hormone replacement 
therapy or any other medication affecting hormone status. Age, 
lifestyle factors, and gynecological and obstetric history of the 
subjects were investigated through a general survey quest-
ionnaire. This study was approved by the ethics committee of 
the Catholic University of Daegu, and informed consent was 
obtained from each subject. The 50 subjects were randomly 
assigned to a safflower tea (Saf-tea) group of 34 subjects and 
a placebo group of 16 subjects. Of the 50 subjects, seven from 
the Saf-tea group and three from the placebo group withdrew 
from the study during the 6-month supplementation period, so 
a total of 40 subjects completed the study. The number of subjects 
in the placebo group was rather small compared with that of 
the test group, because it was difficult to recruit more subjects 
for the placebo group due to ethical reasons.
Safflower tea preparation 
Five hundred grams of safflower seeds (safflower seeds: 
Carthamus tinctorious L.) harvested from a farm in Uisong, 
Geyongbuk, Korea were washed, roasted at 200℃ for 5 min, 
ground, and extracted twice with hexane to remove lipids under 
reflux. The defatted seeds were further extracted with 80% 
ethanol, and the extract was used to prepare the granular 
safflower tea. The safflower tea contained 13% extract (w/w), 
ssangwha tea extract, soy isoflavones, glucose, mannitol, 
maltodextrin, lactose, and sodium silicoalumenate (Table 1). The 
ssangwha tea extract was added to help blood circulation as well 
as reduce the bitter taste of the safflower seed extract. A small 
amount of soy isoflavones was added to enhance the isoflavone 
effect in the tea but it was not expected to have any effect alone. 
Glucose was added for palatability, and the remaining ingredients 
were needed to formulate the tea granules. Ten grams of tea 
granules were packaged in each pack, and two packs were taken 
daily by the subjects in the morning and evening, respectively. 
Safflower polyphenol content was estimated to be 72 mg 
including 18 mg of serotonin derivatives, which was comparable 
to the amount recommended for daily intake of safflower tablets 
that had been for sale. The placebo tea was prepared the same 
as the safflower tea except that the safflower extract and soy 
isoflavones were replaced with maltodextrin. 
Study design
The subjects who consented to participate were individually 
interviewed to obtain information on their general and health- 
related characteristics, including diet and anthropometric indices. 
The subjects were also advised not to change their usual diet 
and health-related habits during the test period. One week later, 
fasting blood samples were taken, and bone density was measured 
for baseline data. Each subject was then given enough Saf-tea 
or placebo to last 1 month in a double-blind fashion. They were 
instructed to take two packs in warm water per day, i.e., one 
packet each in the morning and the evening. The same procedure 
was repeated until completion of the 6-month study. Compliance 
for taking the Saf-tea or placebo was encouraged by phone calls 
in addition to counseling as needed for any complications that 
the subjects encountered. During the 6-month test period, blood 
samples were taken at months 3 and 6, and life style factors, 
anthropometric indices, dietary nutrient intakes, and bone density 
were examined at month 6 by the same procedure as used for 
baseline measurements.
Lifestyle and dietary measurements
The questionnaire included questions about demographic 
characteristics and lifestyle and maternal factors. The selected 
lifestyle and maternal factors were cigarette smoking, alcohol 
intake and physical exercise, type of menopause, and experience 
with contraceptive pills or hormone replacement. Dietary intake 
data were collected by a trained dietitian using the 24-hr recall 
method at months 0 and 6 and were analyzed for energy and 
nutrient contents using the computer aided nutritional analysis, 
version 3.0 program developed by The Korean Nutrition Society 
(2005). Phytoestrogen intake from the diet was estimated by food 
frequency, as described in a previous study [15] and that from 
safflower tea was estimated by the safflower seed polyphenol 
contents reported by Kang et al. [8]. 22 Safflower tea, antioxidative effects, and bone
Placebo (n = 13) Saf-tea (n = 27)
Baseline 6 Month Baseline 6 Month
General characteristics
 Age (yrs) 54.0 ± 1.9
1) 55.6 ± 3.6
 Height (cm) 155.6 ± 2.9 154.1 ± 5.0
 Weight (kg) 61.5 ± 8.0 61.6 ± 8.4 56.3 ± 5.6 56.2 ± 6.0
 BMI (kg/m
2) 25.4 ± 3.0 25.4 ± 3.2 23.6 ± 2.5 23.6 ± 2.7
 WHR 0.87 ± 0.06 0.87 ± 0.05 0.84 ± 0.1 0.85 ± 0.06*
Maternal and menopausal characteristics
 Age of menarche (yrs) 16.8 ± 1.5 16.4 ± 1.8
 Age of menopause 50.6 ± 3.0  50.7 ± 3.6
 Duration of menopause 3.4 ± 2.6 5.0 ± 4.1
 Serum FSH (mU/mL) 53.3 ± 22.5 68.0 ± 23.2
 Serum estradiol (pg/mL) 26.8 ± 30.3 17.8 ± 26.0
1) All  values  are  means ± SD.
*  Significantly  different  from  baseline  by  paired  t-test  at  P < 0.05
Table 2. Marternal and menopausal characteristics and anthropomeric indices
of the study subjects
Placebo (n = 13) Saf-tea (n = 27)
P
2)
Baseline 6 Month Baseline 6 Month
Energy (kcal) 1,494 ± 341
1) 1,523 ± 353 1,621 ± 285 1,542 ± 301 0.690 
Protein (g) 60.0 ± 14.0  58.5 ± 12.4 60.0 ± 14.5 61.7 ± 15.4 0.539 
Fat (g) 30.9 ± 9.2 31.0 ± 14.3 30.0 ± 11.1 32.8 ± 13.2 0.556 
Carbohydrate 
(g)
242 ± 57 248 ± 52 276 ± 48 246 ± 50* 0.311 
Calcium (mg) 517 ± 213 495 ± 189 529 ± 167 557 ± 216 0.466 
Vitamin A 
(μg RE)
597 ± 426 737 ± 300 542 ± 216 1,002 ± 858* 0.278 
Vitamin C (mg) 139 ± 74 93 ± 32* 154 ± 70 103 ± 37* 0.611 
Vitamin E 
(mg  α-TE)
7.6 ± 2.0 8.2 ± 5.3 9.1 ± 3.4 8.0 ± 3.2 0.566 
1) All  values  are  means ± SD.
2) By  ANCOVA  of  changes  from  baseline  between  placebo  and  Saf-tea  groups
* Significantly  different  from  baseline  by  paired  t-test  at  P < 0.05
Table 3. Changes in daily energy, Ca and vitamins A, C, E intakes of the study
subjects after six months of safflower tea supplementation
Blood analysis 
Serum genistein was quantified using time-resolved fluoroim-
munoassay with a Labmaster (Turku, Finland) Genestein kit 
(1212-2003), and enterolactone was quantified in the same 
manner with a Labmaster Enterolactone kit (1212-2001). Serum 
contents of α-tocopherol and retinol were determined by high 
performance liquid chromatography [16] with slight modifi-
cations, after serum samples were extracted with hexane. A C-18 
µBondapak (300 × 8 mm) stainless steel column (Waters, Milford, 
MA, USA) was used, and the analysis was performed isocratically 
with methanol/H2O (97:3,v/v) as the mobile phase and ultraviolet 
detection at 292 nm. Serum thiobarbituric acid reactive substances 
(TBARS) were measured by the methods of Yagi [17] using 
1,1,3,3,-tetraethoxypropane as the standard. Serum osteocalcin was 
measured by the IRMA method with a Osteocalcin-IRMA kit 
from Biosourse
TM (Invitrogen, Carlsbad, CA, USA). Fasting blood 
samples were analyzed for serum alanine amintransferase (ALT), 
aspartate amintransferase (AST), blood urea nitrogen (BUN), and 
creatinine with an automated analyzer (Cobas Integra 700, Roche, 
Switzerland). 
Bone density measurements
Bone mineral density (BMD) of the lumbar spine (L1-L4) was 
measured using dual energy X-ray absorptiometry (Hologic 
QDR-4500, Waltham, MA, U.S.A) at baseline and after 6 months 
of tea supplementation. Regions of interest for the lumbar spine 
were defined according to the manufacturer's guidelines. All 
measurements were made and analyzed by experienced operators 
at Catholic University’s Daegu Hospital. The in vivo precision 
error for BMD was 1%.
Statistical analysis
A chi-square-test was used to investigate if there were any 
differences in general characteristics and lifestyle factors between 
the test and placebo groups at baseline. Paired t-tests were used 
to compare the blood analysis, anthropometric and dietary 
measurement, and BMD data in the test and placebo groups 
before and after supplementation. An analysis of covariance 
(ANCOVA) was used to evaluate differences in values before 
and after supplementation between the test and placebo groups. 
All analyses were performed using the SPSS package (SPSS, 
Inc., Chicago, IL, USA). 
Results
General subject characteristics 
The ages of the subjects ranged from 49 to 64 years, with 
a mean ± standard deviation of 54.0 ± 1.9 years for the placebo 
group and 55.6 ± 3.6 years for the Saf-tea group. Both groups 
had similar heights, weights, body mass indices (BMI), and 
waist-hip ratios (WHR), which did not change in the placebo 
or Saf-tea groups during the 6-month supplementation period, 
except for a slight increase in WHR in the Saf-tea group (Table 
2). The maternal and menopausal characteristics of the subjects 
were not different between the placebo and Saf-tea groups, and 
menopause was confirmed in both groups by estradiol levels 
lower than 30-400 pg/mL. Drinking, smoking, and exercise habits 
were similar between the placebo and the Saf-tea groups and 
did not change during the 6-month supplementation period. 
Nutrient intake of the subjects
Table 3 presents the dietary intake of nutrients, calcium, and 
vitamins A, C, and E in the placebo and Saf-tea groups before 
and after 6 months of supplementation. The Saf-tea group 
appeared to have a slightly higher energy intake than the placebo 
group at baseline and this seemed to be due to a somewhat higher Sung-Hee Cho et al. 23
Baseline 6 Month Difference P value
2) P value
3)
Genistein (nmol/L)
  Placebo (n = 13) 192 ± 153
1) 189 ± 139 -3 ± 213 0.957 0.047
  Saf-tea (n = 27) 178 ± 126 303 ± 165 125 ± 190 0.002
Enterolactone (nmol/L)
  Placebo (n = 13) 48 ± 31  30 ± 12 -18 ± 27 0.074 0.040 
  Saf-tea (n = 27) 37 ± 24  68 ± 42 32 ± 52 0.019
1) All  values  are  means ± SD.
2) By  paired  t-test  between  baselin  and  6  mon
3) By  ANCOVA  of  changes  from  baseline  between  placebo  and  Saf-tea  groups
Table 5. Changes in serum genistein and enterolactone levels of the subjects
after six months of safflower tea supplementation
Phytoestrogen Placebo group (n = 13) Saf-tea group (n = 27)
Source Diet Diet Saf-tea
 Daidzein 19.64 ± 9.52
1) 21.11 ± 10.83
 Genistein 19.70 ± 9.49 21.18 ± 10.86
Total isofavone 39.35 ± 19.00 42.30 ± 21.69 29
2)
 Matairesinol 0.13 ± 0.19 0.11 ± 0.09
 Secoisolariciresinol 0.41 ± 0.24 0.34 ± 0.15
 Enterolactone 0.63 ± 0.30 0.59 ± 0.27
 Enterodiol 0.76 ± 0.64 0.58 ± 0.29
Total lignans 1.92 ± 1.08 1.17 ± 0.51 26.2
Coumesterol 11.19 ± 6.92 16.76 ± 28.07 0
Total phytoestrogen 52.46 ± 19.04 60.23 ± 39.12 54.2
Serotonin derivatives 0 0 18
1) All  values  are  means ± SD.
2) O f 2 9  m g , 1 8  m g  w a s  s u p p lie d  fro m  s o y  is o fla v o n e  in c lu d e d  in  s afflower  tea.
Table 4. Intakes of total phytoestrogen and serotonin derivatives of the subjects
Baseline 6 Month Difference P value
2) P value
3)
Serum osteocalcin (nmol/L)
Placebo 
(n = 13)
21.09 ± 7.55
1) 22.22 ± 8.49 1.12 ± 7.73 0.609 0.076
Saf-tea
(n = 27)
25.06 ± 11.60 23.32 ± 10.2 -1.74 ± 4.10 0.036
Urinary DPD/creatinine (mmol/mmol)
Placebo 8.20 ± 3.00 7.59 ± 2.02 -0.61 ± 2.76 0.443 0.620 
Saf-tea 7.93 ± 2.35 7.88 ± 2.44 -0.04 ± 2.08 0.918
BMD (g/cm
2)
 L1
Placebo 0.79 ± 0.14 0.76 ± 0.14 -0.03 ± 0.56 0.097 0.318
Saf-tea 0.75 ± 0.14 0.74 ± 0.13 -0.01 ± 0.04 0.327
 L2
Placebo 0.89 ± 0.10 0.88 ± 0.10 -0.01 ± 0.03 0.288 0.904
Saf-tea 0.86 ± 0.17 0.84 ± 0.17 -0.01 ± 0.04 0.169
 L3
Placebo 0.94 ± 0.12 0.93 ± 0.13 -0.02 ± 0.28 0.053 0.458
Saf-tea 0.92 ± 0.18 0.91 ± 0.19 -0.01 ± 0.04 0.416
 L4
Placebo 1.00 ± 0.13 0.95 ± 0.12 -0.21 ± 0.04 0.085 0.202
Saf-tea 0.96 ± 0.19 0.97 ± 0.17 0.00 ± 0.05 0.068
 L1~L4
Placebo 0.90 ± 0.12 0.88 ± 0.11 -0.12 ± 0.02 0.014 0.378
Saf-tea 0.87 ± 0.87 0.87 ± 0.16 -0.01 ± 0.03 0.257
1) All  values  are  means ± SD.
2) By  paired  t-test  between  baseline  and  6  mon
3) By  ANCOVA  of  changes  from  baseline  between  placebo  and  Saf-tea  groups
Table 6. Changes in indices of bone status of the subjects after six months of
safflower tea supplementation
intake of carbohydrate. But throughout the study period, no 
significant changes in either the placebo or Saf-tea group were 
observed before and after supplementation, except for vitamin 
A intake, which was higher at 6 months than at baseline in the 
Saf-tea group. After 6 months, changes in nutrient intake, 
including other nutrients not shown in Table 3, did not differ 
between the placebo and Saf-tea groups. 
Phytoestrogen intake and body status
Daily phytoestrogen intake by the subjects was estimated from 
the diet at baseline and from the safflower tea (Table 4). The 
dietary phytoestrogens included isoflavones (daidzein, genistein, 
formononectin, and biochanin A), coumesterol, and ligans 
(matairesinol, secoisolarciresinol, enterolactone, and enteroldiol). 
Daidzein and genistein comprised the majority of dietary 
phytoestrogen isoflavones at 70-75%, whereas coumestetol and 
lignan were found at 22-28% and 2-4%, respectively. The intake 
of total dietary phytoestrogens appeared higher, although not 
significantly, in the Saf-tea group that was supplemented with 
an additional 54.2 mg of phytoestrogen plus 18 mg of serotonin 
derivatives from the tea. This resulted in a more than two-fold 
higher intake of phytoestrogen and serotonin derivatives in the 
Saf-tea group than the placebo group. 
Several kinds of phytoestrogens were ingested by the subjects, 
but only serum levels of genestein and enterolactone, which are 
major metabolites of isoflavones and lignans, were measured in 
this study. The concentrations of serum genistein in the placebo 
and Saf-tea groups were 192 ± 153 and 178 ± 126 nmol/L, 
respectively, at baseline, which were not significantly different 
(Table 5). However, serum genistein levels increased significantly 
in the Saf-tea group following 6 months of tea supplementation 
compared to baseline values, and differences in the genestein 
levels of the placebo group before and after supplementation were 
observed. The same result was found for changes in serum 
enterolactone levels. The enterolactone level at baseline (37 ±
24 nmol/L) in the Saf-tea group almost doubled to 68 ± 42 
nmol/L after Saf-tea supplementation, whereas it decreased 
slightly in the placebo group. 
Bone marker levels and BMD
Table 6 shows serum osteocalcin levels, urinary deoxypyri-
dinoline (DPD) excretion, and lumbar-spine BMD at several bone 
locations in the placebo and Saf-tea study groups before and after 
6 months of tea supplementation. Serum osteocalcin did not 
change in the placebo group but decreased in the Saf-tea group 
after 6 months; however, the Saf-tea group did not show greater 
decreases than the placebo group for the differences between the 24 Safflower tea, antioxidative effects, and bone
Fig. 1. Changes in serum cocnentrations of retinol, α-tocopherol and ascorbic 
acid of the subjects after three and six months of safflower tea supplementation. 
*,** Significantly different from baseline by paired t-test at P < 0.05 and P < 0.001. 
*** Significantly different from baseline by paired t-test at P<0.001 and from placebo 
group  by  ANCOVA  at  P < 0.05.
Baseline 6 Month Difference
Mean ± SE Mean ± SE Mean ± SE
BUN (mg/dl)
Placebo 14.9 ± 3.6
1) 15.1 ± 3.6 0.2 ± 3.1 
Saf-tea 13.9 ± 2.9 13.0 ± 2.7 -0.9 ± 3.0 
Creatinine (mg/dl)
Placebo 0.90 ± 0.11 0.91 ± 0.09 0.01 ± 0.10 
Saf-tea 0.90 ± 0.18 0.92 ± 0.10 0.01 ± 0.09 
AST (IU/l)
Placebo 33.5 ± 33.6 28.1 ± 11.5 -5.5 ± 33.2 
Saf-tea 23.8 ± 5.0 21.9 ± 7.2 -1.9 ± 6.9 
ALT (IU/l)
Placebo 38.5 ± 44.6 33.5 ± 25.2 -5.0 ± 42.5 
Saf-tea 23.1 ± 7.7 21.3 ± 10.6 -1.8 ± 6.9 
1) All  values  are  means ± SD.
Table 7. The changes in concentrations of serum BUN, creatinine, AST and
ALT of study subjects after six months of safflower tea supplementation
Fig. 2. Changes in serum cocnentrations of TBARS of the subjects after three 
and six months of safflower tea supplementation. ** Significantly  different  from 
baseline  by  paired  t-test  and  from  placebo  group  by  ANCOVA  at  P < 0.05.
baseline and 6-month values (P= 0.076 by ANCOVA). Urinary 
DPD excretion was not changed by Saf-tea supplementation. 
BMD (L1-L4) decreased in the placebo group but not in the 
Saf-tea group after 6 months of supplementation, although the 
differences between the baseline and 6-month values of the two 
groups did not show safflower tea effects. 
Antioxidant vitamin and TBARS levels
Fig. 1 shows the serum levels of retinol, α-tocopherol, and 
ascorbic acid for the study subjects before and during 6 months 
of supplementation with the placebo and Saf-tea. Levels of each 
vitamin were not different in the placebo and Saf-tea groups at 
baseline. Retinol levels did not change after 3 months but 
increased both in the placebo (P = 0.011) and Saf-tea tea (P =
0.000) groups after 6 months (both 0.46 ± 0.10 µg/ml) compared 
to baseline values (0.53 ± 0.09 and 0.58 ± 0.14 µg/ml, respectively), 
and no difference (P= 0.168 by ANCOVA) in retinol level were 
observed between the placebo and Saf-tea groups after 6 months 
of supplementation (Fig. 1A). α-Tocopherol appeared to decrease 
in the placebo group after 3 months but returned to baseline after 
6 months (Fig. 1B). However, α-tocopherol increased significantly 
in the Saf-tea group (P = 0.000) after 6 months (12.75 ± 4.36 
µg/ml), compared to the value (9.00 ± 2.26 µg/ml) at baseline 
and at 3 months. Differences between baseline and 6-month α
-tocopherol values were significantly higher in the Saf-tea group 
than in the placebo group (P = 0.029 by ANCOVA). Vitamin 
C levels appeared to be the same in the placebo group but 
increased significantly in the Saf-tea group during the 6 months 
(1.10 ± 0.45 µg/ml) compared to baseline levels (0.92 ± 0.44 
µg/ml,  P = 0.036). Nevertheless, no difference (P = 0.175 by 
ANCOVA) in ascorbic acid levels was observed in the placebo 
and Saf-tea groups after 6 months of supplementation (Fig. 1C). Sung-Hee Cho et al. 25
Fig. 2 shows serum TBARS levels in the study groups during 
tea supplementation. TBARS levels did not change in the placebo 
group but appeared to continue to decrease in the Saf-tea group 
during the 6 months, resulting in a significant decrease after 6 
months (1.34 ± 0.32 MDA nmol/ml) compared to baseline (1.50
± 0.3 MDA nmol/ml, P = 0.002). The difference between the 
baseline and 6-month TBARS values was significantly lower in 
the Saf-tea group than the placebo group (P= 0.045 by ANCOVA). 
Table 7 shows serum levels of AST, ALT, BUN, and creatinine 
in the study subjects before and during 6 months of supple-
mentation in the placebo and Saf-tea groups. No differences were 
observed between the groups, time periods, or changes in the 
placebo and Saf-tea groups after 6 months of supplementation.
Discussion
We evaluated the effectiveness and safety of safflower tea 
administered to postmenopausal women to attenuate osteoporosis 
and improve body antioxidant status. Drinking the safflower tea 
provided 72 mg of safflower polyphenols including isoflavones, 
lignans, and serotonin derivatives increased serum content of 
isoflavones and enterolactone, a major metabolite of lignans, 
and probably serotonin, although the latter was not measured. 
Supplementing with flaxseed, a rich source of enterolignan 
precursors (secoisolariciresinol and matairecinol) increases serum 
enterolactone concentrations [18] and the processing of flaxseed 
such as milling and crushing enhances enterolignan bioavailability 
[19] in humans. The intake of matairesinol, a major lignan in 
safflower tea, by the present study subjects was estimated to be 
approximately 10 mg per day, which was lower than that by 
flaxseed supplementation [18,19]. Matairesinol in the safflower 
tea was from a solvent extract, which appeared to be more easily 
available to the body than enterolignans from flaxseed powder. 
It is also noteworthy that the much smaller intake (~18 mg) of 
soy isoflavones included in safflower tea increased serum 
genestein levels compared to 70-200 mg soy isoflavone/day used 
in most supplementation studies [20-22]. This effect may be 
attributable to the serotonin derivatives (18 mg/day), one of the 
major polyphenolic components in the tea. However, the 
increases in body levels of isoflavones and enterolactone did not 
coincide with any improvements in the bone metabolic markers, 
although BMD appeared to remain the same in the safflower 
tea group compared to a decrease in the placebo group after 6 
months of supplementation. The estrogenic bone protection 
activities of isoflavones and lignans have been repeatedly 
suggested and shown in a few animal and cell studies using 
isoflavones from soy and flaxseed but have rarely been confirmed 
in supplementation studies using humans. The main reason may 
be the amount of isoflavones or lignans used in the studies. When 
ovariectomized rats are fed defatted safflower powder [6] or 
ethanol extract [7], 4-4.4 mg of safflower polyphenols per 250 g 
of rat were observed, which is the equivalent of 800-880 mg 
per 50 kg body weight, whereas only 72 mg of safflower polyp-
henols were supplied to the present subjects who weighed 54-55 
kg. Supplementing with isoflavones from soy and red-clover 
reduces bone loss after a 1 year intake of 43.5 mg/day [23] and 
increases BMD following six months of intake of 57-90 mg/day 
in postmenopausal women [24-26]. However, supplementing 
with 118 mg/day of isoflavones for 3 months does not have an 
effect on bone resorption markers [21], and 90 mg/day for 8 
weeks or 96 mg/day for 9 months [27] does not improve BMD 
compared to placebo. Wu et al. [21] indicated that intervening 
with isoflavones (75 mg/day for 1 year) in postmenopausal 
Japanese women has a modest effect on BMD compared to the 
effects found in Westerners, and the effect was shown only at 
Ward's triangle. Lee et al. [28] reported that supplementation 
with three levels of isoflavones (100, 150, 200 mg/day) for 6 
months appeared to reduce both serum osteocalcin and urinary 
excretion of DPD in postmenopausal women. Uesugi et al. [29] 
reported that 62.8 mg/day of isoflavones for 4 weeks reduced 
urinary DPD significantly and serum osteocalcin non-signifi-
cantly in perimenopausal women. The effects of flaxseed lignans 
on bone health have been shown by a much a smaller number 
of human studies compared to those of soy isoflavones. 
Randomized control studies with either postmenopausal women 
[30-32] or adult men [32] did not show any effects on BMD 
and biomarkers following flaxseed supplementation. In contrast, 
Ward et al. [33] warned that feeding flaxseed secoisolariciresinol 
through a mother's milk may reduce bone strength in young rats. 
However, these results do not exclude the possibility of bone 
promoting effects of flaxseed. More discriminating research 
protocols are necessary to demonstrate the effects of components 
from flaxseed or other plants in different age groups and 
physiological states. The present study was the first human study 
on bone using tea containing safflower polyphenols in postmen-
opausal women with a matching placebo group. Although we 
were unable to attain definite positive bone health results, we 
found that the amount of tea used for the 6-month period of 
the present study was acceptable, judging from interviews with 
subjects. The safflower tea used in the present study had a 
considerable amount of serotonin derivatives (~18 mg), which 
is not found in soybeans, flaxseed, or Ssangwha extract. 
Serotonin aids bone formation in growing rats [34], and 
serotonin-abundant safflower seed powder has the same effect 
in rats with bone-fractures [2-5], as well as reducing bone loss 
in ovariectomized rats [6]. Therefore, it is worth attempting to 
use safflower seed products containing higher amounts of 
serotonin and phytoestrogens in human trials employing a 
crossover design to reduce inter-individual variations that seem 
to obscure statistical significance. 
The safflower tea reduced peroxidation status in the body as 
shown by the reduction in serum TBARS levels. This was 
accompanied by an increase in body antioxidant capacity, as seen 
with higher levels of vitamins E, A, and C. Increases in serum 
vitamin concentrations were not related to changes in dietary 26 Safflower tea, antioxidative effects, and bone
intake of the Saf-tea and placebo groups after 6 months of 
supplementation. Therefore, the effects are regarded as being 
mainly from safflower tea polyphenols composed of flavones, 
lignin, and serotonin derivatives, which have radical scavenging 
activity and inhibit lipid peroxidation in in vitro [8,9] and in 
vivo [14] studies. Isoflavones have antioxidant activity [35]. Choi 
et al. [36] reported that supplementing with 200 mg of 
isoflavones/day for 12 weeks increases total antioxidant status 
both in peri- and post-menopausal women. Furthermore, Lee et 
al. [37] reported that 80 mg isoflavones/day decreases plasma 
malondialdehyde and increases total antioxidant status in 
hypercholesterolemic but not in normolipidemic postmenopausal 
women. However, they did not measure body antioxidant 
compounds individually. The flaxseed lignan secoisolariciresinol 
and its metabolites enterolactone and enterodiol exert antioxidant 
activity within in vitro systems [38,39]. Prasad [38] showed 
decreases in aortic malondialdehyde concentrations in rabbits fed 
a high cholesterol diet. In humans, dietary intake of 50 g of 
flaxseed for 4 weeks does not affect plasma hydroperoxide levels 
[40], whereas low serum enterodiol concentrations are associated 
with increased lipid oxidation [41]. The following studies with 
postmenopausal women failed to show antioxidant activity in 
humans supplemented with flaxseed for 4 weeks [42], or by a 
6-week supplementation with 500 mg of secoisolariciresinol 
isolated from flaxseed [43]. In contrast, we found definite 
antioxidant effects with safflower tea containing 72 mg of safflower 
polyphenols, less than the amount used in the soy isoflavone 
and flaxseed lignan studies.
Our results showed that the safflower tea had strong antioxidant 
activity that helped reduce the incidence of degenerative disease 
in old age and has the potential to maintain bone health in 
postmenopausal women.
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